The earnings call highlighted strong financial performance and successful product launches, particularly with CRENESSITY and INGREZZA, alongside robust pipeline development. However, there are notable challenges such as the failure of the valbenazine study to meet its primary endpoint and pricing pressures on INGREZZA. Despite these challenges, the overall sentiment reflects confidence in continued growth and strategic investments.

Company Guidance -

Q3 2025

In the second quarter of 2025, Neurocrine Biosciences reported strong financial performance with $682 million in net product sales, reflecting a 17% year-over-year growth. The company highlighted its success in driving double-digit growth, particularly through its products INGREZZA and CRENESSITY. INGREZZA achieved $624 million in sales for the quarter, supported by strategic investments in payer access, which resulted in a record number of new patient starts and increased market share. Meanwhile, CRENESSITY's early performance exceeded expectations, growing from $15 million in Q1 2025 to $53 million in Q2 2025, with over 75% of prescriptions being reimbursed. The strong product profile and high unmet needs in the classical congenital adrenal hyperplasia community have positioned CRENESSITY as a potential blockbuster. Looking ahead, Neurocrine has adjusted its INGREZZA net sales guidance to a range of $2.5 billion to $2.55 billion for 2025, while continuing to invest in its diversified neuroscience pipeline, including multiple Phase III programs. The company maintains a robust balance sheet with $1.8 billion in cash, supporting its growth and strategic initiatives.

Strong Financial Performance

Neurocrine Biosciences reported $682 million in net product sales during the second quarter of 2025, representing 17% year-over-year growth.

Successful Launch of CRENESSITY

CRENESSITY grew from $15 million in Q1 2025 to $53 million in Q2 2025, reflecting strong early adoption with over 75% of all dispensed prescriptions being reimbursed.

INGREZZA Growth

INGREZZA delivered $624 million in second-quarter sales, including a record number of new patient starts, and showed gains in prescription market share.

Robust Pipeline Development

Initiated multiple Phase III programs including osavampator in major depressive disorder and NBI-'568 in schizophrenia. A Phase I study for NBIP-1435, a new biological compound, was also launched.

Neurocrine (NBIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NBIX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	1.58 / -	1.24	―	―	―
Jul 30, 2025	2025 (Q2)	0.96 / 1.06	0.63	68.25% (+0.43)
May 05, 2025	2025 (Q1)	0.54 / 0.08	0.42	-80.95% (-0.34)
Feb 06, 2025	2024 (Q4)	1.61 / 1.00	1.44	-30.56% (-0.44)
Oct 30, 2024	2024 (Q3)	1.50 / 1.24	0.82	51.22% (+0.42)
Aug 01, 2024	2024 (Q2)	1.13 / 0.63	0.95	-33.68% (-0.32)
May 01, 2024	2024 (Q1)	1.10 / 0.42	-0.79	153.16% (+1.21)
Feb 07, 2024	2023 (Q4)	1.21 / 1.44	0.88	63.64% (+0.56)
Oct 31, 2023	2023 (Q3)	1.04 / 0.82	0.69	18.84% (+0.13)
Aug 01, 2023	2023 (Q2)	0.81 / 0.95	-0.18	627.78% (+1.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NBIX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$136.76	$128.23	-6.24%
May 05, 2025	$109.75	$118.92	+8.36%
Feb 06, 2025	$150.51	$122.62	-18.53%
Oct 30, 2024	$116.19	$124.33	+7.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neurocrine (NBIX) report earnings?

Neurocrine (NBIX) is schdueled to report earning on Nov 04, 2025, After Close (Confirmed).

What is Neurocrine (NBIX) earnings time?

Neurocrine (NBIX) earnings time is at Nov 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NBIX EPS forecast?

NBIX EPS forecast for the fiscal quarter 2025 (Q3) is 1.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing